argenx SE (BVMF:A1RG34)

Market Cap	262.49B +11.8%
Revenue (ttm)	19.63B +93.0%
Net Income	8.17B
EPS	124.02
Shares Out	n/a
PE Ratio	32.12
Forward PE	27.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	280
Average Volume	146
Open	178.73
Previous Close	n/a
Day's Range	178.73 - 178.73
52-Week Range	116.88 - 200.20
Beta	-0.17
RSI	51.67
Earnings Date	Feb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,599
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1RG34

Financial Performance

Financial numbers in USD